TheStreet Ratings

10 Best Biotech Stocks for

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology

Source: TheStreet Ratings

Best Investments for

Biotechnology News

The departure of Biogen's CEO could lead to a sale of the biotech company, or a renewed push to boost its own M&A activities.
7/21/16 8:11AM
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
7/19/16 7:01AM
Brainstorm's NurOwn is a personalized stem cell treatment designed to slow the progression of ALS, a fatal neurodegenerative disease.
7/18/16 8:01AM
Serious questions about the XBiotech colon cancer drug were raised after the Xylonix presentation at an ESMO cancer meeting on July 2.
7/14/16 10:18PM
The circumstances surrounding the Ziopharm patient deaths come amid heightened scrutiny of experimental anti-cancer therapies.
7/14/16 9:31PM
Santhera's timetable for approval in the U.S. of its Duchenne drug Raxone is pushed back to 2020 after the FDA said a second, successful phase III study will be required.
7/14/16 8:46AM
GED-0301 is one of three drugs -- Otezla and ozanimod are the others -- which form the core of Celgene's burgeoning immunology and inflammation franchise.
7/14/16 7:55AM
The trial found 70% of women with postpartum depression treated with SAGE-547 achieved no more depression after 60 hours compared to just under 10% of women treated with placebo.
7/12/16 8:32AM
The aldoxorubicin sarcoma study failure leaves CytRx with a depleted pipeline and 40 cents per share in cash.
7/11/16 4:41PM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
7/8/16 6:58AM
Juno Therapeutics reminds investors yet again that the business of biotech -- developing new medicines that are effective and reasonably safe -- is hard to get right.
7/8/16 6:50AM
The lead CAR-T program of Juno Therapeutics has been placed on a clinical hold by U.S. regulators following the deaths of two patients in a pivotal clinical trial.
7/7/16 4:54PM
Every day without bad news from Sarepta boosts odds Western blots performed on patients' muscle samples came back with enough eteplirsen dystrophin production to warrant sending the data to FDA.
7/5/16 11:56AM
If the messy, confused clinical data disclosed Saturday by XBiotech are any indication, an approval in Europe for its colon cancer drug is far from a sure thing.
7/5/16 8:35AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
7/1/16 7:01AM